The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

Using alectinib in postoperative adjuvant therapy significantly reduces both the recurrence rate and recurrence-related treatment costs for stage IB (tumor ≥ 4 cm) to IIIA ALK+ NSCLC patients, compared to platinum-based chemotherapy. From perspective of Chinese healthcare system, this approach shows substantial potential for preventing recurrence and achieving cost savings.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-02-05
DOI
https://doi.org/10.3389/fpubh.2025.1571980
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

Yilong WU, N Jovanoski, Xiaohua Ying, B. Jiang et al.
Frontiers in Public Health
Lung Cancer Treatments and Mutations
article

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

Yilong WU, N Jovanoski, Xiaohua Ying, B. Jiang, Melina Arnold, Jingwen Lu, Xuanxuan Yan, Jiahao Hu, Sijuan Zhou, Yan Xia, Haotian He, Jian Hu, Yong Zhang, Pingping Song
article en

Abstract

Using alectinib in postoperative adjuvant therapy significantly reduces both the recurrence rate and recurrence-related treatment costs for stage IB (tumor ≥ 4 cm) to IIIA ALK+ NSCLC patients, compared to platinum-based chemotherapy. From perspective of Chinese healthcare system, this approach shows substantial potential for preventing recurrence and achieving cost savings.

Frontiers in Public HealthVol. 13
Roche (Switzerland) (CH), Academy of Medical Sciences (GB), Sun Yat-sen University (CN), Fudan University (CN), Institute of Technology Assessment (AT), Shanghai Medical Information Center (CN), Shanghai University of Traditional Chinese Medicine (CN), Shandong Tumor Hospital (CN), Roche (China) (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Development Research Center (CN), Guangdong Academy of Medical Sciences (CN), Shuguang Hospital (CN), Shandong First Medical University (CN), First Affiliated Hospital Zhejiang University (CN)
Good health and well-being
Openalex Percentile: Top 67%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer — Yilong WU, N Jovanoski, et al. · Frontiers in Public Health (2026) | TGRS Research Map | TGRS